Expert Health Advice from Our Chief Medical Officer Griffin Hospital Chief Medical Officer and Infectious Diseases Physician Dr. Frederick Browne is a regular guest on WICC's Melissa in the Morning. More than 200 passengers are sick with norovirus on a luxury cruise ship. Dr. Browne discusses what you need to know about this type of sickness and what to do to protect yourself on your next cruise. Listen to the interview here - https://audioboom.com/posts/8699709-melissa-in-the-morning-norovirus-outbreak (fb)

Introducing Sleep Bound The Sleep Wellness Center at Griffin Hospital recently launched a new “Sleep Bound” program to provide comprehensive care that may include GLP-1 weight-loss medication to address both obstructive sleep apnea and obesity. The U.S. Food and Drug Administration (FDA) approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity when paired with a reduced-calorie diet and increased physical activity. Griffin’s Sleep Bound program will work with patients to develop an individualized treatment plan that could include Zepbound. To qualify for the program, individuals will need to a have a qualifying baseline sleep study (preferably within the last two years), demonstrate moderate to severe sleep apnea, and meet a certain Body Mass Index (BMI) threshold. After significant weight loss, participants will repeat their sleep study to re-evaluate the status of their obstructive sleep apnea. Eligible patients may qualify for Zepbound with insurance authorization. Patient exclusions from the program include current use of other GLP-1 agonist medications, and insulin-dependent diabetes. For more information on how to qualify for Sleep Bound, visit www.griffinhealth.org/sleepbound or contact Pulmonary Specialties at 203-732-7573. (fb)